Cystic Fibrosis Foundation issued the following clinical trial alerts in October:
October 3, 2022
Study to evaluate the standardizing of treatment for pulmonary exacerbations in children and adults with CF ages 6 and older.
Description: This study will look at pulmonary exacerbations, which are a worsening of respiratory symptoms, in people with CF who need to be treated with intravenous (IV) antibiotics. It will compare treatment with one antibiotic (a beta-lactam) to treatment with two antibiotics (tobramycin and a beta-lactam) to learn whether there is a difference in lung function and symptom improvement between the two groups. This study is for people ages 6 and older.
Age: 6 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: No FEV1 Limit
Number of Visits: 3
Length of Participation: 48 days
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT05548283
October 27, 2022
Study of galicaftor/navocaftor/ABBV-576 combination therapy in adults with cystic fibrosis who have at least one F508del mutation and are on stable elexacaftor/tezacaftor/ivacaftor (Trikafta) treatment.
Description: This study will look at the safety and effectiveness of the galicaftor/navocaftor/ABBV-576 combination therapy, a combination of CFTR modulators intended to help CFTR protein function closer to normal. This study is for adults with cystic fibrosis who have at least one F508del mutation.
Age: 18 Years and Older
Mutation: Two Copies F508del or One Copy F508del
Fev1% Predicted: 40 to 90%
Number of Visits: 6
Length of Participation: 3 months
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT04853368